EyePoint (EYPT) Stock Crashes 71% Today. Here Is What Happened
TLDR
- EYPT stock hit a 52-week low of $4.06, dropping over 71% on August 17, 2026
- The Phase 3 LUGANO trial of DURAVYU missed its primary visual acuity endpoint in the full dataset
- An ad hoc analysis excluding a small asymmetric patient cohort did show non-inferiority versus aflibercept
- Secondary outcomes were positive, including a 42% reduction in treatment burden versus aflibercept
- EyePoint still plans to file with U.S. regulators in the first half of 2027, pending LUCIA trial data
EyePoint Pharmaceuticals (EYPT) stock fell more than 71% on August 17, 2026, hitting a 52-week low of $4.06 after the company reported topline results from its pivotal Phase 3 LUGANO trial.
EyePoint Pharmaceuticals, Inc., EYPT
The trial tested DURAVYU 2.7 mg in patients with wet age-related macular degeneration. The drug failed to meet its primary visual acuity endpoint when measured across the full patient dataset.
That’s the headline investors reacted to, and the sell-off was swift.
EyePoint did offer some context. In an ad hoc analysis that excluded a small cohort of patients whose vision loss was unrelated to wet AMD, DURAVYU showed non-inferiority to on-label aflibercept. But ad hoc analyses carry less regulatory weight than the pre-specified primary endpoint, and the market priced that in fast.
… Continue reading the full article at the original source below.
